Article Text

Download PDFPDF
Review: pharmacological and psychological interventions decrease cannabis use in people with depressive and psychotic disorders in the short term

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.



Do pharmacological or psychological interventions improve cannabis use outcomes in people with psychotic or depressive disorders?


Cannabis use.



Systematic review.

Data sources

PubMed (from commencement) and PsycINFO (from commencement) to December 2008.

Study selection and analysis

Randomised controlled trials (RCTs) of pharmacological or psychological interventions reporting cannabis use outcomes in people with psychotic or depressive disorders were included in the review. Exclusions: non-English language studies.

Main results

Seven trials met inclusion criteria. Two RCTs reported cannabis use outcomes following pharmacological interventions: one in people with major depression, alcohol dependence and cannabis abuse diagnoses (n=22; fluoxetine vs placebo) and one in people with schizophrenia and cannabis and/or cocaine use disorders (n=28; olanzapine vs risperidone). Psychotherapy was included for all participants, and neither study assessed a pharmacological intervention specifically designed to reduce cannabis use. In the study in people with major depression, cannabis …

View Full Text


  • Sources of funding National Health and Medical Research Council and the Colonial Foundation.


  • Competing interests None.

Linked Articles